ACELRX PHARMACEUTICALS INC Uncategorized Contracts & Agreements
16 Contracts & Agreements
- Form of CVR Agreement (Filed With SEC on November 15, 2021)
- Promotion Agreement among the Registrant, La Jolla Pharmaceutical Company and Tetraphase Pharmaceuticals, Inc., effective September 30, 2020 (Filed With SEC on November 5, 2020)
- Amendment No. 1 to Co-Promotion Agreement, dated as of May 26, 2020, by and between the Registrant and Tetraphase (Filed With SEC on May 29, 2020)
- Form of Revised CVR Agreement (Filed With SEC on May 29, 2020)
- Form of Revised CVR Agreement (Filed With SEC on May 27, 2020)
- Amendment to Agreement between the Registrant and SpecGX, LLC, dated September 23, 2019 (Filed With SEC on November 7, 2019)
- Agreement between the Registrant and SpecGX, LLC, dated June 16, 2017 (Filed With SEC on November 7, 2019)
- Offer Letter dated March 16, 2018 with John Saia (Filed With SEC on March 27, 2018)
- QUANTITY (Filed With SEC on March 10, 2017)
- QUANTITY (Filed With SEC on August 4, 2015)
- SECOND AMENDMENT TO AMENDED AND RESTATED CAPITAL EXPENDITURE AND EQUIPMENT AGREEMENT (Filed With SEC on May 8, 2014)
- /s/ Richard King (Filed With SEC on May 8, 2014)
- AMENDED AND RESTATED CAPITAL EXPENDITURE AND EQUIPMENTAGREEMENT (Filed With SEC on May 8, 2013)
- QUARTERLY REPORT FORMAT (Filed With SEC on August 11, 2011)
- FOUNDERS VESTING AGREEMENT (Filed With SEC on January 7, 2011)
- FOUNDERS VESTING AGREEMENT (Filed With SEC on January 7, 2011)
